Vir Biotechnology Shares Rise Nearly 10% in Premarket After Gilead Deal

Vir Biotechnology shares traded nearly 10% higher in premarket trading on Oct. 14 after the company announced a licensing agreement with Gilead to use its PRO-XTEN platform for cancer drug discovery and development. The agreement is valued at up to nearly $1.9 billion. Gilead will use Vir’s masking technology platform to discover and develop cancer drugs. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.